7.78

0.25% -0.07

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $7.78, with a volume of 111.95K. It is down -0.25% in the last 24 hours and down -2.37% over the past month. INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Previous Close:

$7.85

Open:

$7.74

24h Volume:

111.95K

Relative Volume:

0.32

Market Cap:

$174.05M

Revenue:

$155.00K

Net Income/Loss:

$-30.01M

P/E Ratio:

-4.6587

EPS:

-1.67

Net Cash Flow:

$-11.98M

1W Performance:

-8.85%

1M Performance:

-2.37%

6M Performance:

+14.64%

1Y Performance:

-33.76%

1-Day Range:

$7.30

$8.135

1-Week Range:

$7.30

$8.69

52-Week Range:

$4.32

$13.30

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2024-10-31

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	7.83	174.05M	155.00K	-30.01M	-11.98M	-1.67
VRTX Vertex Pharmaceuticals Inc	475.44	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	695.98	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	617.05	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	241.50	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	267.85	29.71B	3.32B	-860.46M	-1.04B	-8.32

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Feb 27, 2025

Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St

Feb 27, 2025

Feb 24, 2025

INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews

Feb 24, 2025

Feb 23, 2025

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Feb 23, 2025

Feb 21, 2025

INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire

Feb 21, 2025

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 20, 2025

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World

Feb 18, 2025

Feb 16, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat

Feb 16, 2025

Feb 14, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says - MarketBeat

Feb 14, 2025

Feb 13, 2025

Raymond James raises INmune Bio stock target to $23 By Investing.com - Investing.com Nigeria

Feb 12, 2025

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - The Manila Times

Feb 12, 2025

INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment - Nasdaq

Feb 12, 2025

Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating - TipRanks

Feb 12, 2025

INmune Bio’s CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com Nigeria

Feb 12, 2025

Scotiabank raises INmune Bio stock target to $23 on new therapy - MSN

Feb 12, 2025

INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World

Feb 12, 2025

Feb 11, 2025

INmune Bio's CORDStrom shows promise in RDEB treatment - MSN

Feb 11, 2025

Market Insight: INmune Bio Inc (INMB)’s Notable Drop, Closing at 9.12 - The Dwinnex

Feb 11, 2025

Scotiabank raises INmune Bio stock target to $23 on new therapy By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 10, 2025

BLA Submission Planned for CORDStrom in RDEB - MD Magazine

Feb 10, 2025

Inmune Bio Secures License Agreement for CORDStrom Data - TipRanks

Feb 10, 2025

INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe -February 10, 2025 at 10:26 am EST - Marketscreener.com

Feb 10, 2025

Inmune Bio Completes Phase 2 Trial for CORDStrom - TipRanks

Feb 10, 2025

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Markets Insider

Feb 10, 2025

INmune Bio's CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com South Africa

Feb 10, 2025

INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom - StreetInsider.com

Feb 10, 2025

Feb 07, 2025

Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat

Feb 07, 2025

Feb 05, 2025